News

iBio has received a U.S. patent for its method of increasing the amount and quality of endostatin-derived peptides generated from the company’s plant-based FastPharming protein production system. These peptides, which have been shown to possess strong anti-fibrotic or anti-scarring properties, make up part of IBIO-100, an experimental…

The U.S. Food and Drug Administration (FDA) has granted treprostinil orphan drug designation for the treatment of idiopathic pulmonary fibrosis (IPF). Orphan drug designation is given to therapies with the potential to substantially improve treatment for rare diseases (conditions affecting fewer than 200,000 people in the U.S.). The designation…

The global COVID-19 pandemic has had a negative local impact on healthcare for most people in the U.K. with pulmonary fibrosis (PF), who have seen their medical appointments canceled, their pulmonary rehabilitation programs halted, and their health status decline as a result of lockdowns and other safety measures,…

The nonprofit Three Lakes Foundation and the healthcare incubator MATTER announced the four winners of the 2020 Innovation Challenge, an initiative that promotes advancements in the way pulmonary fibrosis (PF) is diagnosed, treated, and managed. Winners of the challenge will receive a monetary award…

GLPG1205, an investigational therapy by Galapagos, was found to be safe and well tolerated, with an ability to lower lung function decline in adults with idiopathic pulmonary fibrosis (IPF), according to results from a Phase 2 clinical trial. Top-line data from the study, called PINTA (…

A Phase 3 clinical trial evaluating Bellerophon Therapeutics’ investigational therapy INOpulse — inhaled nitric oxide — in patients with pulmonary fibrosis (PF) at risk of developing pulmonary hypertension (PH) has enrolled its first patient. Top-line data from the trial, called REBUILD (NCT03267108), are expected by 2022. “We…

To empower and equip members of the rare disease community to engage state leaders in matters of importance to patients and their families, the National Organization for Rare Disorders (NORD) has launched an initiative across the U.S. Its goal is to establish a Rare Disease Advisory Council (RDAC)…

The new documentary “Beyond Breathless,” spotlighting interstitial lung disease (ILD) patients and their families, will feature actress and producer Queen Latifah and former NY Yankee Bernie Williams. “Beyond Breathless” premieres on the…

The National Institutes of Health (NIH) has awarded a researcher at the University of Pennsylvania the K08 Award for his research in pulmonary fibrosis (PF), the Pulmonary Fibrosis Foundation (PFF) announced. PFF scholar Jeremy Katzen, MD, is the recipient of the NIH career development award for…

NeuroScientific Biopharmaceuticals, the Institute for Respiratory Health, and the University of Western Australia (UWA) have initiated a preclinical study assessing the potential of EmtinB and other related, lab-made compounds to treat post-COVID pulmonary fibrosis. Post-COVID fibrosis is irreversible scarring of the lungs…